Targeting CD20 in chronic lymphocytic leukemia

Myrna R Nahas, Jon E ArnasonBeth Israel Deaconess Medical Center, Boston, MA, USAAbstract: Chronic lymphocytic leukemia (CLL), the most common leukemia in adults, is standardly managed with chemotherapy in combination with the anti-CD20 antibody rituximab. In this review, we discuss the history, us...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Nahas MR, Arnason JE
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2015
Materias:	Diseases of the blood and blood-forming organs RC633-647.5
Acceso en línea:	https://doaj.org/article/5553e19ee40f47e3a977ac5250db6693
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:5553e19ee40f47e3a977ac5250db6693
record_format	dspace
spelling	oai:doaj.org-article:5553e19ee40f47e3a977ac5250db66932021-12-02T06:52:18ZTargeting CD20 in chronic lymphocytic leukemia1179-9889https://doaj.org/article/5553e19ee40f47e3a977ac5250db66932015-03-01T00:00:00Zhttp://www.dovepress.com/targeting-cd20-in-chronic-lymphocytic-leukemia-peer-reviewed-article-BLCTThttps://doaj.org/toc/1179-9889 Myrna R Nahas, Jon E ArnasonBeth Israel Deaconess Medical Center, Boston, MA, USAAbstract: Chronic lymphocytic leukemia (CLL), the most common leukemia in adults, is standardly managed with chemotherapy in combination with the anti-CD20 antibody rituximab. In this review, we discuss the history, use, and evolution of rituximab in the treatment of CLL and explore the next generation CD20 antibodies ofatumumab and obinutuzumab with a focus on recent clinical trials. Increased understanding of the importance of B cell receptor (BCR) signaling in CLL has resulted in the development of several drugs with significant clinical activity that are ideally suited for combination with CD20 therapy as is being currently explored. Moving forward, these developments have the potential to result in treatment regimens that do not include traditional chemotherapeutic agents, which is of particular importance in CLL given the late onset of diagnosis and potential frailty of the patients.Keywords: CLL, monoclonal antibody, rituximab, ofatumumab, obinutuzumabNahas MRArnason JEDove Medical PressarticleDiseases of the blood and blood-forming organsRC633-647.5ENBlood and Lymphatic Cancer: Targets and Therapy, Vol 2015, Iss default, Pp 43-53 (2015)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diseases of the blood and blood-forming organs RC633-647.5
spellingShingle	Diseases of the blood and blood-forming organs RC633-647.5 Nahas MR Arnason JE Targeting CD20 in chronic lymphocytic leukemia
description	Myrna R Nahas, Jon E ArnasonBeth Israel Deaconess Medical Center, Boston, MA, USAAbstract: Chronic lymphocytic leukemia (CLL), the most common leukemia in adults, is standardly managed with chemotherapy in combination with the anti-CD20 antibody rituximab. In this review, we discuss the history, use, and evolution of rituximab in the treatment of CLL and explore the next generation CD20 antibodies ofatumumab and obinutuzumab with a focus on recent clinical trials. Increased understanding of the importance of B cell receptor (BCR) signaling in CLL has resulted in the development of several drugs with significant clinical activity that are ideally suited for combination with CD20 therapy as is being currently explored. Moving forward, these developments have the potential to result in treatment regimens that do not include traditional chemotherapeutic agents, which is of particular importance in CLL given the late onset of diagnosis and potential frailty of the patients.Keywords: CLL, monoclonal antibody, rituximab, ofatumumab, obinutuzumab
format	article
author	Nahas MR Arnason JE
author_facet	Nahas MR Arnason JE
author_sort	Nahas MR
title	Targeting CD20 in chronic lymphocytic leukemia
title_short	Targeting CD20 in chronic lymphocytic leukemia
title_full	Targeting CD20 in chronic lymphocytic leukemia
title_fullStr	Targeting CD20 in chronic lymphocytic leukemia
title_full_unstemmed	Targeting CD20 in chronic lymphocytic leukemia
title_sort	targeting cd20 in chronic lymphocytic leukemia
publisher	Dove Medical Press
publishDate	2015
url	https://doaj.org/article/5553e19ee40f47e3a977ac5250db6693
work_keys_str_mv	AT nahasmr targetingcd20inchroniclymphocyticleukemia AT arnasonje targetingcd20inchroniclymphocyticleukemia
_version_	1718399691288215552

Targeting CD20 in chronic lymphocytic leukemia

Ejemplares similares